
C-terminal fragment of α-MSH (Lys-Pro-Val) — potent anti-inflammatory with special affinity for intestinal and skin mucosa.
Ranges cited in research literature. Not a usage recommendation. For research use only.
KPV is a tripeptide — lysine, proline, valine — matching the last three amino acids (11-13) of α-melanocyte-stimulating hormone (α-MSH). The full thirteen-amino-acid α-MSH has two faces: a pigmentary one, mediated by melanocortin receptors, and an anti-inflammatory one. The KPV fragment keeps the second and loses the first, which made it a tool for studying inflammation without interfering with melanogenesis.
Its mechanism is peculiar in that it needs no melanocortin receptor. In intestinal epithelial cells and keratinocytes it enters through the oligopeptide transporter PepT1, accumulates in the cytoplasm and inhibits the nuclear translocation of NF-κB, with the ensuing drop in IL-6, IL-8, TNF-α and other cytokines. In murine colitis models (DSS and TNBS) it reduced inflammation and histological damage, and in allergic contact dermatitis models it dampened the cutaneous inflammatory response.
All evidence is preclinical: cell cultures and rodents, with the reference study by Dalmasso and colleagues in Gastroenterology (2008). There are no published human clinical trials and no regulatory status as a drug. Because of its minimal size it is highly soluble and relatively stable, although like any reconstituted peptide it must be kept cold. Renova distributes it for research only, individually and as a component of the KLOW blend.
| Class | Tripeptide, C-terminal fragment of α-MSH (residues 11-13) |
| Sequence | Lys-Pro-Val (3 aa) |
| CAS | 67727-97-3 |
| Mechanism | PepT1 uptake → NF-κB inhibition; no activity at melanocortin receptors |
| Models studied | Murine colitis (DSS, TNBS); contact dermatitis; keratinocytes and Caco-2 epithelium |
| Status | Preclinical; no human trials, no approval |
| Properties | Highly water-soluble; no associated pigmentation; no cysteine or methionine (low oxidation sensitivity) |
| Renova presentations | Individual 10 mg vial; component of the KLOW blend |
No. The pigmentary action of α-MSH depends on melanocortin receptors, and KPV does not activate them; it keeps only the hormone's anti-inflammatory region. That is precisely why it was isolated as a fragment: to study inflammation with no effect on melanogenesis.
Mainly in induced colitis in mice (DSS and TNBS) and in skin inflammation, plus cultures of intestinal epithelial cells and keratinocytes. The reference work is Dalmasso et al. in Gastroenterology (2008). There are no human clinical trials.
Through PepT1, the di- and tripeptide transporter the gut uses to absorb protein-digestion products. It is highly expressed in the intestinal epithelium, which explains why KPV's effect is most evident in the colonic mucosa.
The individual vial contains 10 mg of KPV and allows studying it in isolation or at whatever ratio is decided. In KLOW it comes fixed alongside BPC-157, GHK-Cu and TB-500 in one vial. Our KPV guide and the GLOW vs KLOW guide explain the contexts for each option.
Related reading: KPV: Anti-inflammatory Tripeptide for Skin & Mucosa · KLOW: The Repair Blend with KPV · HHS and peptide compounding in the U.S.: the October 2026 policy and its 10 conditions
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty